Products
Precision medicine service for liver cancer
From 2006, top tier liver cancer clinical research with highest-quality of data worldwide via collaborative research with top class research institutes(Ajou University Hospital, Samsung Medicial center, and Asan medical center etc.). It's leading to world-class research outputs and commercialized products.
The precision medicine service provides one-stop test that includes sample assay and genomic data analysis to facilitate
- determination of cancer treatment on surgery
- determination of therapeutic interventions
- selection of alternative off-label interventions to serve all patients suffering from liver cancer.
The service is expected to launch in the first half of 2020.
<OncoHePaTest® Scientific Publication> Cancer Science 101(6): 1521-1528
<New Health Technology> The Ministry of Health and Welfare: 2010-83
<OncoHePaTest® KIT Certificate> KFDA Notice 13-511, Domestic & Worldwide patents WO2010120143A2, WO2010120143A3
Successful validation of OncoHePaTest® in Japanese HCV-HCC patients
- predict 5-year survival / 2-year recurrence in HCV derived HCC patients (Japanese)
Successful validation of OncoHePaTest® in small solitary HCC patients, Ann Surg Treat Res. 2018 Dec;95(6):303-311
- predict 5-year survival/recurrence in small solitary HCC patients
Biomarker pipelines for cancer drug repositioning
Pipeline | Drug Development | Phase I | Phase II | Phase III | |
---|---|---|---|---|---|
Biomarker Development | Single center Validation | Multi-center validation (Global) | |||
PROGNOSTICS | HCC | OncoHepaTest® | |||
CRC | PCRT | ||||
HNSCC | Prognosis | ||||
TNBC | Prognosis | ||||
HCC | TACE | ||||
Liver Fibrosis | Prognosis of progressiveness | ||||
PREDICTIVE | HCC Nexavar® (ORR) | ||||
HCC Nexavar® (DCR) | |||||
TNBC Doxorubicin + Cyclophosphamide | |||||
HNSCC First line palliative therapy | |||||
SCLC Keytruda + Taxol | |||||
PSC IMFINZI + Tremelimumab (Immune therapy) | |||||
ACC Axitinib |